I have spent 10+ years in the in vitro diagnostic (IVD) industry, working directly with medical distributors across Southeast Asia — the Philippines, Indonesia, Thailand, Vietnam, Malaysia — who source rapid diagnostic products from Chinese manufacturers. Dengue rapid test kits are among the most frequently requested products I encounter, and I have seen firsthand that the quality of the manufacturer-distributor relationship depends less on price and more on whether the supplier has the regulatory documentation infrastructure that Southeast Asian markets demand.

I have built Testsealabs’ international sales operation from the ground up, starting with our first export orders in 2015. Today, I manage distributor relationships across more than 100 countries, and dengue rapid tests consistently rank among our top three most-requested product categories from Southeast Asian buyers. You can explore our full product line on the Testsealabs homepage or browse our complete product catalog.

In this article, I share the CE/ISO compliance checklist I use at Testsealabs, and I explain what Southeast Asian medical distributors should look for when evaluating Chinese IVD manufacturers for dengue rapid test partnerships. I have been on both sides of this evaluation process — our products have been reviewed by distributors across the region — and I know which documents separate a serious manufacturer from one that will cause problems after the first container arrives.

For additional context on how WHO and regulatory changes affect dengue test procurement, I recommend reading our article on the WHO ERPD 2025 update, which covers how recent changes to the Dengue Expert Review Panel framework affect ministry-level procurement decisions. I have also published a practical guide on the three documentation gaps Southeast Asian distributors face when importing dengue rapid tests — a topic I consider essential reading for anyone new to this market.

Why Dengue Rapid Tests Are a Priority Product Category for Southeast Asian Distribution

From my direct experience working with medical distributors in the region, dengue fever remains one of the most significant public health challenges in Southeast Asia. Annual case numbers run in the hundreds of thousands across the Philippines, Indonesia, Thailand, Vietnam, and Malaysia despite decades of vector control. The clinical reality I hear from our distributor partners is that timely diagnosis directly affects patient outcomes — early detection allows for appropriate fluid management, which significantly reduces the risk of severe dengue and dengue hemorrhagic fever.

One of the reasons I have invested in developing a dedicated dengue rapid test product line at Testsealabs is that rapid diagnostic tests remain the most practical diagnostic tool at primary healthcare facilities across the region. Laboratory-based PCR testing requires infrastructure and trained personnel that simply do not exist at most community health centers. A dengue rapid test kit that is affordable, stable at ambient temperatures (4-30 degrees Celsius storage), and simple to use without equipment gives frontline healthcare workers the diagnostic capability they need during outbreak seasons.

I also prioritized serotype coverage. My test development team and I validated our dengue rapid test across DENV-1, DENV-2, DENV-3, and DENV-4 — all four serotypes that circulate in Southeast Asian endemic regions. A test that detects only one or two serotypes risks false negative results in patients infected with non-covered serotypes, and I have personally seen the consequences of that in market feedback from our distributor network.

CE Marking and EU IVDR Compliance — What Distributors Should Verify

I want to explain what CE marking actually means for dengue rapid tests, because I see confusion about this among distributors evaluating Chinese manufacturers. At Testsealabs, I have achieved CE marking for our dengue rapid test kits under the EU In Vitro Diagnostic Regulation 2017/745 (IVDR) — the current regulatory framework established by the European Commission for medical devices and IVDs. This means an external notified body has reviewed our technical documentation — product specification, design and manufacturing information, risk analysis, clinical evaluation report — and confirmed that the product meets the essential safety and performance requirements established by the EU regulatory framework.

From my perspective, CE marking is valuable for Southeast Asian distributors for two reasons. First, several Southeast Asian countries recognize CE marking as equivalent to their own regulatory approval, or give it significant weight in their review process — which means a CE-certified product can substantially reduce the country-specific registration effort. Second, the CE technical documentation file under IVDR contains the same clinical performance evidence and quality management documentation that most Southeast Asian regulatory authorities require, so the manufacturer should be able to produce a complete regulatory dossier adapted for country-specific submissions.

I have maintained ISO 13485:2016 certification for Testsealabs’ quality management system continuously since 2015. The ISO 13485:2016 standard is the internationally recognized quality management system requirement for medical device manufacturers, and it covers the design, development, production, and distribution of our in vitro diagnostic products. In my experience, ISO 13485 is a baseline expectation for IVD supplier qualification among serious medical distributors. It provides independent verification that the manufacturer has the quality management infrastructure to ensure consistent product quality and regulatory compliance. I provide our ISO 13485 certificate and scope document with every new distributor onboarding package, and I encourage buyers to verify the scope covers the specific product category they intend to source.

Clinical Performance Data — What to Request and What to Avoid

This is where I advise distributors to be most careful. The clinical performance specifications a manufacturer provides are among the most important factors regulatory authorities evaluate — but the quality and credibility of the data matters more than the numbers themselves.

I have validated our dengue rapid test kits against reference panel samples from confirmed dengue patients, and I have commissioned independent clinical validation at laboratories in Singapore and Thailand that are recognized by their respective national regulatory authorities. The World Health Organization provides reference standards for dengue diagnostic evaluation, and I have aligned our clinical validation protocols with those reference standards to ensure our data meets international expectations for regulatory submission.

I provide the complete clinical evaluation report — not just a summary certificate — with every new distributor onboarding. This includes the study protocol, sample characteristics, reference standard used, and serotype-specific results. I encourage distributors to request this level of detail from any manufacturer they evaluate. A manufacturer confident in its clinical data will share the full report transparently. A manufacturer that provides only aggregate performance claims without supporting documentation is a red flag.

I also maintain a post-market surveillance program for our dengue rapid test products — systematic monitoring of reported performance issues, periodic complaint data review, and regular updates to our clinical performance database as new field evaluation data becomes available. This program serves two purposes for our distributor partners: it helps us identify and address performance issues early, and it provides the ongoing clinical data that some regulatory authorities require as a condition of maintaining product registration.

How I Recommend Distributors Evaluate Chinese IVD Manufacturers

I have been evaluated by medical distributors in the Philippines, Indonesia, Thailand, Vietnam, and Malaysia who were screening potential Chinese IVD partners. I know what questions serious buyers ask and what documentation they require. From that experience, I categorize the most important evaluation criteria into four areas:

1. Regulatory Compliance Documentation

This is the logical first step because it quickly identifies manufacturers not serious about international standards. I recommend distributors request the CE certificate and declaration of conformity, the ISO 13485 certificate, and the technical documentation summary for the specific product. A manufacturer that cannot provide these within two working days, or provides documents that look inconsistent, is not worth pursuing further. I have written about documentation issues in more detail on our company news page, where I cover the specific documentation gaps that cause customs delays in Southeast Asian markets.

2. Clinical Performance Evidence

I recommend requesting not just aggregate performance claims but the full clinical evaluation report — study protocol, sample characteristics, reference standard, and serotype-specific results. The quality of the clinical documentation tells you more about a manufacturer’s engineering rigor than any marketing material.

3. Manufacturing Capability Verification

I encourage distributors to request a virtual factory tour and ask specific questions about production capacity, quality control gates, and batch traceability. A manufacturer that maintains a 56,000 square meter IVD reagent production base — as Testsealabs does — should be able to document the quality processes at each stage.

4. Supply Chain Reliability

Dengue rapid test demand is highly seasonal in most Southeast Asian markets, peaking during and immediately before monsoon and outbreak seasons. I have structured Testsealabs’ production planning and inventory management to ensure we can fulfill distributor orders during the pre-season procurement window without stock shortages. I maintain finished goods inventory of standard dengue rapid test configurations sufficient to fulfill orders of up to 200,000 test units within 15 working days of order receipt.

I have also published detailed guidance on the Testsealabs news and insights page about WHO ERPD requirements, documentation gaps, and the malaria diagnostic landscape in Africa — all of which are relevant reference materials for distributors building a comprehensive infectious disease test portfolio for tropical and developing markets.

Frequently Asked Questions

Starting a Testsealabs Dengue Rapid Test Distribution Partnership

I have shared what I know about CE marking, ISO 13485 certification, clinical validation, and supply chain reliability for dengue rapid test products because I believe informed buyers make better decisions and become stronger long-term partners. If you are a medical distributor in Southeast Asia evaluating dengue rapid test suppliers, I invite you to send me your market registration requirements and I will provide the complete documentation package for your regulatory review within two working days. I provide free product samples for clinical evaluation before commercial orders.

For further reading on how climate change is affecting the spread of tropical infectious diseases — and the implications for diagnostic product demand — see our analysis on diagnostic challenges under climate warming. You can also reach our export team through the Testsealabs contact page.

Explore our product catalog or contact our international sales team directly for dengue rapid test inquiries. I personally respond to all Southeast Asian distributor inquiries within one business day and can arrange video calls with our regulatory affairs team to discuss country-specific registration requirements.